Top

Published in:

01-11-2007 | Letter to the Editor

Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature

Authors: Nimit Singhal, Sudarshan Selva-Nayagam, Michael P Brown

Published in: Journal of Neuro-Oncology | Issue 2/2007

Abstract

Temozolomide is an alkylating agent used frequently in the management of gliomas. Although temozolomide is generally safe, rarely it can cause life threatening complications. Here we report the cases of two patients who developed prolonged and severe pancytopenia after low dose continuous temozolomide concurrently with cranial radiotherapy. The pancytopenia lasted two to six months. Both the patients were young, treatment naïve, and had temozolomide treatment for only approximately four weeks.

Stupp R, Mason WP, van den Bent MJ et al (2005) radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef

Spence AM, Kiem HP, Partap S, Schuetze S, Silber JR, Peterson RA (2006) Complications of a temozolomide overdose: a case report. J Neuro-Oncol 80:57–61CrossRef

Hartmann P, Herholz K, Salzberger B, Petereit HF (2004) Unusual and severe symptomatic impairment of neutrophil function after one cycle of temozolomide in patients with malignant gliomas. Ann Hematol 83:212–217PubMedCrossRef

Su YW, Chang MC, Chiang MF, Hsieh RK (2005) Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neuro-Oncol 71(3):315–318CrossRef

Noronha V, Berliner N, Ballen KK, Lacy J, Kracher J, Baehring J, Henson JW (2006) Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro-oncol 8(3):280–283PubMedCrossRef

Doyle TJ, Mikkelsen T, Croteau D et al (2005) Fatal hematologic toxicity with prolonged continuous administration of temozolomide (TMZ) during radiation therapy (RT) in the treatment of newly-diagnosed glioblastoma multiforme (GBM): Report of a Phase II trial. J Clin Oncol, ASCO Annual Meeting Proceedings 23 (16S):1546

Villano JL, Collins CA, Manasanch EE et al (2006) Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 7:436–438PubMedCrossRef

Fink D, Aebi S, Howell SB (1998) The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4:1–6PubMed

Title: Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature
Authors: Nimit Singhal
Sudarshan Selva-Nayagam
Michael P Brown
Publication date: 01-11-2007
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2007
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-007-9403-6

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2007

Racial/ethnic differences in survival among elderly patients with a primary glioblastoma

Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly

Hyperoxia retards growth and induces apoptosis, changes in vascular density and gene expression in transplanted gliomas in nude rats

Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression

Valproic acid induces p21 and topoisomerase-II (α/β) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines

A cerebral teratoma in an unusual location